Summary
In vitro and ex-vivo studies show that befloxatone, a new oxazolidinone derivative, is a potent, reversible, competitive and specific MAO-A inhibitor (KiA from 1.9 to 3.6 nM and KiB/KiA ratio between 100 and 400, in the Rat and in Man, depending on the tissue). Befloxatone possesses a marked activity in antidepressant-sensitive behavioral models in rats (from 0.03 to 0.15 mg/kg po) and mice (from 0.21 to 0.29 mg/kg po). At these doses, befloxatone does not induce a significant potentiation of oral tyramine. Befloxatone is devoid of sedative, anticholinergic and cardiovascular effects. Befloxatone is rapidly and extensively distributed in rat brain, the pharmacokinetics are linear in the rat and in man in a large range of doses. Befloxatone is well tolerated in healthy volunteers and is developed as an antidepressant.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Amrein R, Allen SR, Vranesic D, Stabl M (1988) Antidepressant drug threrapy: associated risks. J Neural Transm [Suppl] 26: 73–86.
Ansseau M, Caillé P, Derks C, Cieren-Puiseux I, Soubrane C, Wauthy J, Ego D, Curet O, Thiola A, Rovei V, Jarreau FX (1992a) Phase I study of single ascending doses of Befloxatone, a new reversible MAO-A inhibitor antidepressant. Proceedings XVIII CINP, Nice. Clin Neuropharmacol 15: 328B.
Ansseau M, Caillé P, Derks C, Cieren-Puiseux I, Soubrane C, Wauthy J, Ego D, Rovei V, Jarreau FX (1992b) Phase I study of repeated doses of Befloxatone, a new reversible MAO-A inhibitor antidepressant. Proceedings XVIII CINP, Nice. Clin Neuropharmacol 15: 328B.
Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm [Suppl] 28: 21–31.
Callingham BA (1992) Possible drug interactions with reversible MAO inhibitors. Proc XVIII CINP Nice 1992. Clin Neuropharmacol [Suppl 1] 15: 71–225.
Curet O, Damoiseau G, Labaune JP, Rovei V, Jarreau FX (1992) Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. 5th International Amine Oxidase Workshop, Galway (Ireland) (unpublished).
Da Prada M, Zurcher G, Wutrich I, Haefely WE (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm 26: 31–56.
Ego D, Parisy D, Pattano N (1992) Pharmacokinetics of befloxatone, a new reversible inhibitor of MAO-A in rat. Proceedings XVII CINP Nice. Clin Neuropharmacol 15: 422B.
Ferrey G, Rovei V, Strolin Benedetti M, Gomeni C, Languillat JM (1985) Antidepressant activity of toloxatone, a selective MAO-A inhibitor, in depressed patients. In: Burrows GD, Norman TR, Dennerstein L (eds) Clinical and pharmacological studies in psychiatric disorders. John Libbey, London Paris, pp 83–86.
Fitton A, Faulds D, Goa KL (1992) Moclobemide, a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43: 561–596.
Jarrott B, Vajda FJE (1987) The current status of monoamine oxidase and its inhibitors. Med J Aus 146: 634–638.
Nutt D, Glue P (1989) Monoamine oxidase inhibitors: rehabilitation from recent research?. Br J Psychiatry 154: 287–291.
Paykel ES (1992) Role of monoamine oxidase inhibitors in the treatment of affective disorders. Proc 5th World Congress Biological Psychiatry Florence 1991. Royal Society of Medicine Services, London New York, pp 1–8.
Rovei V, Ego D, Jarreau FX (1990) Assessment of the interaction between Humoryl (Toloxatone) and oral tyramine in man vol 1. XVII CINP, Kyoto, p 43.
Tyrer P, Harrison-Read P (1990) New perspectives in treatment with monoamine oxidase inhibitors. Int Rev Psychiatry 2: 331–340.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag
About this paper
Cite this paper
Rovei, V., Caille, D., Curet, O., Ego, D., Jarreau, FX. (1994). Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. In: Tipton, K.F., Youdim, M.B.H., Barwell, C.J., Callingham, B.A., Lyles, G.A. (eds) Amine Oxidases: Function and Dysfunction. Journal of Neural Transmission, vol 41. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9324-2_45
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9324-2_45
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82521-1
Online ISBN: 978-3-7091-9324-2
eBook Packages: Springer Book Archive